Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

CAR T cell therapy: looking back and looking forward

Subjects

Recent progress indicates a considerably improved mechanistic understanding of CAR T cell biology and delivers important insights into why some patients achieve durable remissions and others do not. In addition, although most success has been achieved in the context of CAR T cells targeted to B cell tumor antigens, namely CD19 and BCMA, we are seeing promising clinical trial outcomes for solid tumor malignancies.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Brentjens, R. J. et al. Sci. Transl. Med. 5, 177ra138 (2013).

    Article  Google Scholar 

  2. Locke, F. L. et al. N. Engl. J. Med. 386, 640–654 (2022).

    Article  CAS  Google Scholar 

  3. Kamdar, M. et al. Lancet 399, 2294–2308 (2022).

    Article  CAS  Google Scholar 

  4. Jain, M. D. Mol. Ther. 30, 14–16 (2022).

    Article  CAS  Google Scholar 

  5. Melenhorst, J. J. et al. Nature 602, 503–509 (2022).

    Article  CAS  Google Scholar 

  6. Haradhvala, N. J. et al. Nat. Med. 28, 1848–1859 (2022).

    Article  CAS  Google Scholar 

  7. Good, Z. et al. Nat. Med. 28, 1860–1871 (2022).

    Article  CAS  Google Scholar 

  8. Lee, J. C. et al. Cancer Res. 71, 2871–2881 (2011).

    Article  CAS  Google Scholar 

  9. Scholler, N. et al. Nat. Med. 28, 1872–1882 (2022).

    Article  CAS  Google Scholar 

  10. Jain, M. D. et al. Blood 137, 2621–2633 (2021).

    Article  CAS  Google Scholar 

  11. Faramand, R. et al. Clin. Cancer Res. 26, 4823–4831 (2020).

    Article  CAS  Google Scholar 

  12. Jain, M. D. et al. Blood 140, 491–503 (2022).

    Article  CAS  Google Scholar 

  13. Mailankody, S. et al. N. Engl. J. Med. 387, 1196–1206 (2022).

  14. Qi, C. et al. Nat. Med. 28, 1189–1198 (2022).

    Article  CAS  Google Scholar 

  15. Narayan, V. et al. Nat. Med. 28, 724–734 (2022).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Renier J. Brentjens.

Ethics declarations

Competing interests

M.L.D. has equity or options to purchase equity in Bellicum, Precision Biosciences and Adicet. M.L.D. has received licensing revenue from CRISPR and Atara Biotherapeutics. M.L.D. has received fees from Adicet, Syncopation, Synthekine and Bellicum. R.J.B. has licensed intellectual property to and collect royalties from Bristol Myers Squibb (BMS), Caribou and Sanofi. R.J.B. received research funding from BMS. R.J.B. is a consultant to BMS, Atara Biotherapeutics, Coimmune and Triumvira, and was a consultant for Gracell Biotechnologies, but ended employment in the past 24 months. R.J.B. is a member of the scientific advisory board for CoImmune and Triumvira.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Davila, M.L., Brentjens, R.J. CAR T cell therapy: looking back and looking forward. Nat Cancer 3, 1418–1419 (2022). https://doi.org/10.1038/s43018-022-00484-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-022-00484-w

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer